NPM1 and acute myeloid leukemia: Since an increased rate of DNMT3A-R882 mutations was observed for our short-lived subgroup, we also analyzed a large independent cohort of AML patients34 and observed an enrichment of DNMT3A-R882 and NPM1 co-mutations and an enrichment of concurrent DNMT3A-R882, NPM1, and FLT3 mutations compared to AML patients with DNMT3A mutations that did not affect the R882 codon.